Some months ago, Sen. Charles Grassley (R-Iowa), who has been investigating the safety of health information technology, sent a letter to Health and Human Services Secretary Kathleen Sebelius asking for her views on whether the Food and Drug Administration should regulate health I.T. products.

Grassley wasn't coy. One of his questions was: "With over $20 billion in taxpayer money at stake and with increasing complexity in the technologies being used in our hospitals, do you believe it is time to revisit FDA's responsibilities in regulating HIT products being used in clinical care?"

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access